Innovative Platforms
Empowering Pet Drug Research and Development
While pet health has received increasing attention in recent years, the development of pet drugs still faces numerous challenges, such as limitations in drug delivery methods, low compliance in administering medications to pets, and a lack of effective therapies for complex diseases. As a CRO/CDMO focused on the pet pharmaceutical sector, Protheragen Vetivo has established five core innovative platforms, committed to effectively addressing the challenges in pet drug development through cutting-edge technologies and advancing pet healthcare.
Flash-Release Tablet Platform
Addressing the challenges of difficult drug administration and low compliance in pets.
Utilizing lyophilization and flash-release technology, flash-release tablets disintegrate rapidly within seconds upon contact with saliva in the pet’s oral cavity, enabling instant drug release. This innovation is especially suited for pets that struggle to swallow conventional tablets or capsules.
Oral Thin Film Platform
Providing a convenient and pleasant experience for pets.
The API is uniformly dispersed in a soluble polymer matrix to form an ultrathin, palatable film strip. Simply place the oral thin film in the pet's mouth, no chewing or water is required. The oral thin film dissolves within seconds, allowing the active ingredients to be absorbed through the oral mucosa for quick effects.
Monoclonal Antibody Platform
Providing highly targeted and safe biological therapies for complex chronic diseases.
Leveraging hybridoma or recombinant DNA technology, we develop high-specificity and high-affinity monoclonal antibodies (mAbs) drugs targeting specific disease pathways in pets. This platform offers targeted treatment for complex and chronic conditions with high specificity and minimal side effects, overcoming the limitations of traditional small-molecule drugs, such as insufficient efficacy or significant adverse effects.
siRNA Platform
Achieving precision targeting of diseases at the genetic level.
Through the RNA interference mechanism, this platform specifically degrades disease-related messenger RNA in pets, preventing the production of harmful proteins at the translational level. It targets traditionally "undruggable" pathways, offering a novel gene-silencing therapeutic strategy for genetic disorders, chronic diseases, viral infections, and more in pets.
mRNA Platform
Programming cellular machinery to treat and prevent pet disease.
We design and synthesize mRNA molecules encoding specific target proteins. Delivered into cells via advanced systems (e.g., lipid nanoparticles, LNPs), these molecules instruct the host cells to produce therapeutic or immunogenic proteins. This platform enables rapid adaptation to evolving pathogens and development of safer, highly effective next-generation pet vaccines.
